GNI And EpiCept Ink Development Deal For Anti-Viral Hepatitis B Drug
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - GNI and EpiCept have entered into an agreement that will see the latter develop a new anti-viral hepatitis B drug, EP1013, in Asia, Australia and New Zealand